Granted Patent B2

US 9,109,032 · App. 13/571,827 · Granted Aug 18, 2015

Abstract

Claims (14)

1. A method of treating a patient that has a hematological proliferative disorder where less than 20% of the hematological proliferative disorder cells express EphA3, and aberrant vasculature in bone marrow is EphA3+, the method comprising administering a therapeutically effective amount of an anti-EphA3 antibody to the patient, wherein the anti-EphA3 antibody (i) activates EphA3 and/or (ii) induces ADCC.

2. The method of claim 1 , wherein 5% or less of the hematological proliferative disorder cells express EphA3 and the hematological proliferative disorder is acute myeloid leukemia (AML).

3. The method of claim 1 , wherein 5% or less of the hematological proliferative disorder cells express EphA3 and the hematological proliferative disorder is chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia (ET), or idiopathic myelofibrosis (IM).

4. The method of claim 1 , wherein the hematological proliferative disorder is chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, chronic neutrophilic leukemia, chronic eosinophilic leukemia, or mast cell disease.

5. The method of claim 1 , wherein the anti-EphA3 antibody comprises a human heavy chain gamma-1 or gamma-3 constant region.

6. The method of claim 1 , wherein the anti-EphA3 antibody is provided in a hypofucosylated or afucosylated antibody preparation.

7. The method of claim 1 , wherein the anti-EphA3 antibody induces ADCC.

8. The method of claim 1 , wherein the anti-EphA3 antibody blocks binding of ephrinA5 ligand to EphA3.

9. The method of claim 1 , wherein the anti-EphA3 antibody binds to the epitope on EphA3 to which an antibody having a V H region CDR1 having a sequence SYWIN (SEQ ID NO:2), a V H region CDR2 having a sequence DIYPGSGNTNYDEKFKR (SEQ ID NO:3), a V H region CDR3 having a sequence SGYYEDFDS (SEQ ID NO:4), a V L region CDR1 having a sequence RASQEISGYLG (SEQ ID NO:9), a V L region CDR2 having a sequence AASTLDS (SEQ ID NO:10), and a V L region CDR3 having a sequence VQYANYPYT (SEQ ID NO:11) binds.

10. The method of claim 1 , wherein the anti-EphA3 antibody is a recombinant or chimeric antibody.

11. The method of claim 1 , wherein the anti-EphA3 antibody is a humanized or engineered human antibody.

12. The method of claim 1 , wherein the anti-EphA3 antibody is a monoclonal antibody.

13. The method of claim 1 , wherein the anti-EphA3 antibody is a polyclonal antibody.

14. The method of claim 1 , wherein the anti-EphA3 antibody is a multivalent antibody that comprises a Fab, a Fab′, or an Fv.

Assignments (8)